Terrance G. Johns has not added Biography.
If you are Terrance G. Johns and would like to personalize this page please email our Author Liaison for assistance.
Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
International journal of cancer. Journal international du cancer Mar, 2002 | Pubmed ID: 11920591
The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis.
Proceedings of the National Academy of Sciences of the United States of America Sep, 2003 | Pubmed ID: 12960396
Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.
Hybridoma and hybridomics Aug, 2003 | Pubmed ID: 14511567
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
Proceedings of the National Academy of Sciences of the United States of America Dec, 2003 | Pubmed ID: 14676326
CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.
The Journal of biological chemistry May, 2004 | Pubmed ID: 15016810
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
The Journal of biological chemistry Jul, 2004 | Pubmed ID: 15075331
The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
Oncogene Aug, 2004 | Pubmed ID: 15221011
Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
Cancer immunity : a journal of the Academy of Cancer Immunology Feb, 2005 | Pubmed ID: 15723450
The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology May, 2005 | Pubmed ID: 15774576
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2005 | Pubmed ID: 16144944
Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2005 | Pubmed ID: 16203806
Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.
Biochemistry Nov, 2005 | Pubmed ID: 16274239
An automated peptide and protein thiazolidine coupling chemistry for biosensor immobilization giving a unique N-terminal orientation.
Analytical biochemistry Jan, 2006 | Pubmed ID: 16310754
Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury.
The Journal of neuroscience : the official journal of the Society for Neuroscience Jul, 2006 | Pubmed ID: 16837601
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.
The Journal of biological chemistry Feb, 2007 | Pubmed ID: 17092939
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
Proceedings of the National Academy of Sciences of the United States of America Mar, 2007 | Pubmed ID: 17360479
The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2007 | Pubmed ID: 17363548
Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding.
Biochemistry Apr, 2007 | Pubmed ID: 17381163
Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.
Neoplasia (New York, N.Y.) Dec, 2007 | Pubmed ID: 18084617
Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling.
Circulation research May, 2008 | Pubmed ID: 18436796
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.
Proceedings of the National Academy of Sciences of the United States of America Mar, 2009 | Pubmed ID: 19289842
A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
Growth factors (Chur, Switzerland) Jun, 2009 | Pubmed ID: 19333814
The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Neoplasia (New York, N.Y.) May, 2009 | Pubmed ID: 19412429
Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization.
Journal of cellular and molecular medicine Sep, 2009 | Pubmed ID: 19432811
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Cancer research Sep, 2009 | Pubmed ID: 19690143
Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Jun, 2010 | Pubmed ID: 20484439
MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.
International journal of radiation oncology, biology, physics Oct, 2010 | Pubmed ID: 20638193
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
Genes & development Aug, 2010 | Pubmed ID: 20713517
Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.
Journal of cell science Sep, 2011 | Pubmed ID: 21878501
Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Proceedings of the National Academy of Sciences of the United States of America Feb, 2012 | Pubmed ID: 22323579
JoVEについて
Copyright © 2023 MyJoVE Corporation. All rights reserved